Intangible Assets

Goodwill



(In millions)	CooperVision			CooperSurgical			Total
Balance at October 31, 2016	$	1,646.4		$	518.3		$	2,164.7
Net additions during the year ended October 31, 2017	28.6			94.4			123.0
Translation	60.7			6.4			67.1
Balance at October 31, 2017	1,735.7			619.1			2,354.8
Net additions during the nine months ended July 31, 2018	36.8			34.4			71.2
Translation	(4.3		)	(0.4		)	(4.7		)
Balance at July 31, 2018	$	1,768.2		$	653.1		$	2,421.3

We performed our annual impairment assessment in our third quarter of fiscal 2018 and 2017, and our analysis indicated that we had no impairment of goodwill. We evaluate goodwill for impairment annually during the fiscal third quarter and when an event occurs or circumstances change such that it is reasonably possible that impairment may exist. We account for goodwill and evaluate our goodwill balances and test them for impairment in accordance with related accounting standards.

We performed a qualitative assessment to test each reporting unit's goodwill for impairment. Qualitative factors considered in this assessment include industry and market considerations, overall financial performance and other relevant events and factors affecting each reporting unit. Based on our qualitative assessment, if we determine that the fair value of a reporting unit is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be compared with its carrying amount and an impairment charge will be recognized for the carrying amount which exceeds the reporting unit's fair value. A reporting unit is the level of reporting at which goodwill is tested for impairment. Our reporting units are the same as our business segments - CooperVision and CooperSurgical - reflecting the current way we manage our business. Goodwill impairment analysis and measurement is a process that requires significant judgment. If our common stock price trades below book value per share, there are changes in market conditions or future downturn in our business, or a future annual goodwill impairment test indicates an impairment of our goodwill, we may have to recognize a non-cash impairment of goodwill that could be material and could adversely affect our results of operations in the period recognized and also adversely affect our total assets and stockholders' equity.

Other Intangible Assets



	July 31, 2018				October 31, 2017
(In millions)	Gross Carrying Amount		Accumulated Amortization & Translation		Gross Carrying Amount		Accumulated Amortization & Translation		Weighted Average Amortization Period (In years)

Trademarks	$	139.6	$	14.6	$	44.5	$	10.3	14
Composite intangible asset	1,061.9		53.1		—		—		15
Technology	396.0		183.9		428.8		173.2		11
Customer relationships	354.6		163.6		335.5		145.3		13
License and distribution rights and other	73.3		51.4		69.2		44.5		9
	2,025.4		$	466.6	878.0		$	373.3	14
Less: accumulated amortization and translation	466.6				373.3
Other intangible assets, net	$	1,558.8			$	504.7

In the second quarter of fiscal 2018, CooperSurgical recognized an impairment charge of $24.4 million on the intangible assets acquired from Recombine Inc. as the cash flows expected to be generated by this asset group over its estimated remaining life were not sufficient to recover its carrying value. CooperSurgical acquired Recombine Inc. in fiscal 2016, a clinical genetic testing company specializing in carrier screening. The intangible assets impaired consisted of Technology, Trademark and Customer relationships.

As of July 31, 2018, the estimation of amortization expenses for intangible assets with finite lives is as follows:



Fiscal years:	(In millions)
Remainder of 2018	$	36.3
2019	143.3
2020	133.4
2021	132.2
2022	130.3
Thereafter	974.4
Total remaining amortization for intangible assets	$	1,549.9